1269025-19-5Relevant articles and documents
Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists
Gray, David L.,Xu, Wenjian,Campbell, Brian M.,Dounay, Amy B.,Barta, Nancy,Boroski, Susan,Denny, Lynne,Evans, Lori,Stratman, Nancy,Probert, Al
scheme or table, p. 6604 - 6607 (2010/06/12)
Compounds that are both norepinephrine reuptake inhibitors (NRI) and 5-HT1A partial agonists may have the potential to treat neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD) and depression. Targeted screening